Actively Recruiting

Phase 2
Age: 18Years - 64Years
All Genders
NCT05355272

Growth Hormone Replacement in Veterans With GWI and AGHD (GWIT)

Led by Baylor College of Medicine · Updated on 2026-05-08

20

Participants Needed

2

Research Sites

172 weeks

Total Duration

On this page

Sponsors

B

Baylor College of Medicine

Lead Sponsor

U

United States Department of Defense

Collaborating Sponsor

AI-Summary

What this Trial Is About

The goal of the GWIT Study is to assess whether growth hormone replacement therapy is a safe and effective treatment for veterans with Gulf War Illness (GWI) and adult growth hormone deficiency (AGHD). The main questions the study aims to answer are: 1. Is growth hormone effective at reducing fat in the trunk of the body and symptoms of GWI among veterans with GWI and growth hormone deficiency? 2. Do the results of the study suggest there is merit in pursuing a larger trial to examine the efficacy of growth hormone as a treatment for growth hormone deficiency among veterans with Gulf War Illness? To determine eligibility for the study, veterans will be asked to complete several assessments including questionnaires, blood tests, and a scan of the brain. Participants who qualify for the study will receive recombinant human growth hormone for 6-months. A body composition scan will be performed at Day1, Day 90, and Day 180 of the intervention. Questionnaires and cognitive tests will also be collected before and after the trial.

CONDITIONS

Official Title

Growth Hormone Replacement in Veterans With GWI and AGHD (GWIT)

Who Can Participate

Age: 18Years - 64Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Veteran of the Gulf War conflict with deployment to Operation Desert Storm or Desert Shield between 1990-91
  • Age less than or equal to 64 years old
  • Diagnosed with Gulf War Illness as assessed by study investigators
  • Diagnosed with adult growth hormone deficiency by glucagon stimulation test (cut point 3.0 mcg/L if BMI ≤ 25 or 1.0 mcg/L if BMI > 25)
  • Stable on any psychotropic medications for at least 4 weeks
  • Stable on all hormone treatments for at least 3 months
  • Able and willing to provide informed consent and complete study protocol
Not Eligible

You will not qualify if you...

  • History of psychiatric disorders severely impacting function or quality of life (e.g., schizophrenia, schizoaffective disorder, bipolar, or other psychotic disorders)
  • History of neurologic disorders other than traumatic brain injury that severely impact quality of life
  • Other known causes of growth hormone deficiency such as childhood onset GHD, hypothalamic/pituitary disease, brain radiation history, or genetic mutations causing GHD
  • Active suicidal thoughts (score of 2 or higher on Columbia Suicide Severity Rating Scale)
  • Suicidal behavior in the past 6 months
  • Contraindications to recombinant human growth hormone such as hypersensitivity
  • Acute medical illness, active infection, cancer, or decompensated chronic illnesses (e.g., diabetes, heart failure, COPD)
  • Substance use disorder in past 6 months except mild alcohol or cannabis use diagnosed at screening
  • Urine toxicology showing illicit drug use (excluding cannabis) within past 90 days
  • Body mass index over 35 or body weight over 350 lbs
  • Abnormal pituitary anatomy shown by MRI with Sella protocol
  • Women who are pregnant or of childbearing potential unable or unwilling to use barrier contraception
  • Current use of growth hormone, estrogen or estrogen-like supplements, hormonal contraceptives, progestin, IGF-1, or high-dose glucocorticoids
  • Currently enrolled in other interventional drug trials without prior approval

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

Michael E. DeBakey VA Medical Center

Houston, Texas, United States, 77030

Actively Recruiting

2

VA Puget Sound Healthcare System

Seattle, Washington, United States, 98108

Actively Recruiting

Loading map...

Research Team

L

Lane Witkowski

CONTACT

A

Audri Villalon

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here